Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The end of Qutenza sends NGX-1998 into the neuropathic pain fray

This article was originally published in Scrip

Executive Summary

Following the FDA's rejection of Qutenza (8% capsaicin patch) for the management of HIV-related pain, potential for the product in the future neuropathic pain market will remain limited to postherpetic neuralgia. NeurogesX will shift its focus to the development of NGX-1998 - a more user-friendly, liquid formulation of the drug. However, the shift towards an early pipeline product means that NeurogesX will have to face greater competition in the future neuropathic pain market as a number of agents are topical pipeline agents will provide fierce competition.

You may also be interested in...



Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Topics

Related Companies

UsernamePublicRestriction

Register

WI964947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel